We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
Mannitol or sorbitol, when administered intravenously, or as a component of an irrigation solution or peritoneal dialysis solution, may increase blood mannitol or sorbitol concentrations and cause falsely elevated readings of your sensor glucose results. Sorbitol is used in some artificial sweeteners, and concentration levels from typical dietary intake do not impact sensor glucose results.
Non-clinical testing has demonstrated the Eversense® E3 Sensor is MR Conditional. A patient with this device can be safely scanned in an MR system meeting the following conditions:
Under the scan conditions defined above, non-clinical testing results indicate the Eversense Sensor is expected to produce a maximum temperature rise of less than 5.4 °C after 15 minutes of continuous scanning.
In non-clinical testing, the image artifact caused by the device extends approximately 2.83 inches (72 mm) from the Eversense® E3 Sensor when imaged with a gradient echo pulse sequence and a 3T MR system.
The Eversense Smart Transmitter is MR Unsafe and MUST BE REMOVED before undergoing an MRI procedure. Before you undergo an MRI procedure, tell the MRI staff that you have an Eversense Sensor and Smart Transmitter.
No glucose readings will be displayed. Always charge immediately when the smart transmitter battery is completely drained. The system will return to Initialization phase if the battery is not charged within 16 hours of a Battery Empty alert.
The mobile app will also display a “No Transmitter Detected” status banner.
In the Eversense E3 pivotal clinical trial (PROMISE Study), the system required primarily 1 cal/day, prompting for a median of one-calibration per day 62% of the time, and two calibrations per day 38% of the time, after day 21.
Please visit our Compatibility page for the latest information.
The glucose data is stored in the cloud, not on your mobile device. If you are downloading the App onto a new device, the following data will automatically become available:
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
MKT-001692 Rev 1